Corrections log · updated November 13, 2026
Corrections
Every correction to a figure, a source attribution or a calculation is listed here, with its date and the page that changed. The corrected page also shows its new “Updated” date.
Report an error
Email [email protected] with the page and the source. We review within 7 business days. We correct a page when the cited source says something different, when a figure is credited to the wrong body, or when a calculation is wrong or shown without its formula. Routine updates to newer official data are listed on Price changes; how we check is described on How we verify.
Log
- — Enbrel (Germany): the page cited the statutory price-ceiling list of October 15, 2026 after a newer list had appeared. In the list of November 1, 2026 the lowest Enbrel pharmacy price is €816.19 for four 50 mg pens (previously €820.10), about $912 instead of $916 (€816.19 ÷ 0.89509); the ceiling of €862.63 and the biosimilar prices are unchanged. Also updated in the drug comparison tool.
- — Re-check of ten drug pages against their sources. Januvia: “generics at about $3 to $41 a month” corrected to “$3 to $40” — the correction of the Swiss generic price on November 5 had not reached this sentence. Enbrel: US pharmacy cost for four pens $8,335 → $8,334 (4 × $2,083.62477 = $8,334.499). Stelara: Switzerland $1,872 → $1,871 (CHF 1,540.15 ÷ 0.82295 = $1,871.499). Both had been rounded twice, first to the cent and then up. The Enbrel figure is also corrected in Drug prices by country and the drug comparison tool.
- — Ofev price by country: the takeaway “about nine times what pharmacies now pay for the generic” was published without its formula; it now shows it ($6,538 ÷ $723).
- — Eliquis: “a fifth to a third of the US list price” replaced by “about 19% to 30%”, with the formula ($66 ÷ $346 and $104 ÷ $346). Jardiance: “roughly 20% to 37%” of Medicare’s negotiated price corrected to “about 21% to 37%”, and “an eighth to a fifth” of what US pharmacies pay replaced by “12% to 21%”, with the formula ($41 and $72 ÷ $197, and ÷ $336); a heading with a fraction and no formula was reworded. NovoLog: the heading “a fifth to two-thirds of the US” had no formula and was reworded.
- — Januvia: the cheapest Swiss generic is CHF 30.95 for 28 tablets (Sitagliptin Devatis), not CHF 31.75; its 30-day cost changes from $41 to $40.
- — Enbrel: “about a quarter” of the list price replaced by “about 27%”, with the formula (4 × $583.77 = $2,335; $2,335 ÷ $8,565).
- — Derived percentages on 18 pages: each now shows its formula, or was removed where it only repeated a figure. Two calculations were wrong: LASIK savings 45% → 44% (1 − $2,500 ÷ $4,492) and rhinoplasty 65% → 64% (1 − $2,500 ÷ $7,000).
- — Mounjaro and Wegovy/Zepbound: the estimated minimum price of $40 for a 30-day course (Levi et al., Obesity, 2023) had been described as “at the weight-loss dose”; the study names no dose, so the phrase was removed. Dental crowns: “~$1,500 in the US” corrected to “in Maryland” — the KFF Health News column (2019) reports an insurer average in Maryland.
- — AI transparency pages for eight videos: a caveat copied from the dental-crown video had been repeated on the insulin, Mounjaro, rhinoplasty and Zepbound/Wegovy pages; each now gives its own article’s current figures. On the GLP-1 and Ozempic pages, claims that could not be verified were removed and older video figures are labelled as such; the knee-replacement and LASIK pages now match their articles.
- — Turkish medical-tourism regulation: the 2017 regulation (Official Gazette No. 30123) was repealed on April 26, 2025 by Official Gazette No. 32882, article 17. The pages on choosing a dental clinic in Türkiye and on whether dental implants there are worth it now cite Official Gazette No. 32882, article 5. A heading said “five” checks where the table lists six; corrected.
- Nov 2, 2026 — Turkish Ministry of Health price tariff (hair transplant, rhinoplasty, IVF): it had been described as a "legal minimum"; it is the Ministry's base (floor) price for international patients, in force since Feb 23, 2026, set by ministerial approval rather than by law. Hair transplant: the sentence "our $2,800 estimate sits above that floor" removed — the tariff does not define a follicle as a graft, so the two cannot be compared. Rhinoplasty: an unsourced "US ~$8,000" removed from the title; lira converted at the ECB rate of Oct 30, 2026. IVF: "packages cost more" replaced by what the tariff excludes (travel and hotel). LASIK: the same "legal minimum" wording corrected; lira converted at the ECB rate of Oct 30, 2026 (~$270, previously ~$290 at mid-2026 rates); Femto-LASIK and SMILE tariff lines added.
- Oct 25, 2026 — Source audit of all 25 articles (Oct 22–25): every figure re-checked against the source it cites. Figures credited to bodies that do not publish them (for example dental, rhinoplasty and hair-transplant prices) are now labelled market estimates or removed; outdated figures were moved to the latest data (for example US health spending to 2024, NHS dental access to the August–September 2026 survey wave, Eliquis to its January 2026 list price); unverifiable claims were removed; source lists now point to the specific documents instead of homepages. Each article shows its own “Updated” date.
- Oct 22, 2026 — Insulin: production cost corrected to $48–71 (BMJ Global Health); KFF “1 in 4 paid above $35” dated to 2018, before the caps; rationing figure attributed to Annals of Internal Medicine (2022, 2021 data).
- Oct 21, 2026 — Hair transplant cost per graft: “$4–$10 per graft” had been credited to a peer-reviewed US survey that publishes no per-graft price — now labelled a market estimate; journal name corrected to Aesthetic Plastic Surgery.
- Oct 21, 2026 — Ozempic: “$28–140 per person-year” had been credited to JAMA Network Open; it comes from Levi et al., Obesity (2026). Two unverifiable claims removed.
- Oct 21, 2026 — Hair transplant Turkey vs US: a per-graft price wrongly attributed to ISHRS removed; prices labelled market estimates.